BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33228165)

  • 1. Acellular Pertussis Vaccine Inhibits
    Holubová J; Staněk O; Brázdilová L; Mašín J; Bumba L; Gorringe AR; Alexander F; Šebo P
    Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33228165
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunization with whole cell but not acellular pertussis vaccines primes CD4 T
    Wilk MM; Borkner L; Misiak A; Curham L; Allen AC; Mills KHG
    Emerg Microbes Infect; 2019; 8(1):169-185. PubMed ID: 30866771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.
    Queenan AM; Dowling DJ; Cheng WK; Faé K; Fernandez J; Flynn PJ; Joshi S; Brightman SE; Ramirez J; Serroyen J; Wiertsema S; Fortanier A; van den Dobbelsteen G; Levy O; Poolman J
    Vaccine; 2019 Jan; 37(1):80-89. PubMed ID: 30478007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory CD4 T Cells and Protection Against
    Zurita ME; Wilk MM; Carriquiriborde F; Bartel E; Moreno G; Misiak A; Mills KHG; Hozbor D
    Front Cell Infect Microbiol; 2019; 9():125. PubMed ID: 31106160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal Immunization With a c-di-GMP-Adjuvanted Acellular Pertussis Vaccine Provides Superior Immunity Against
    Jiang W; Wang X; Su Y; Cai L; Li J; Liang J; Gu Q; Sun M; Shi L
    Front Immunol; 2022; 13():878832. PubMed ID: 35493458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a Neonatal-Mouse Model to Characterize Vaccines and Strategies for Overcoming the High Susceptibility and Severity of Pertussis in Early Life.
    Martin Aispuro P; Ambrosis N; Zurita ME; Gaillard ME; Bottero D; Hozbor DF
    Front Microbiol; 2020; 11():723. PubMed ID: 32362890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of maternal whole-cell or acellular pertussis primary immunization on neonatal immune response.
    Martin Aispuro P; Bottero D; Zurita ME; Gaillard ME; Hozbor DF
    Front Immunol; 2023; 14():1192119. PubMed ID: 37435078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model.
    Misiak A; Leuzzi R; Allen AC; Galletti B; Baudner BC; D'Oro U; O'Hagan DT; Pizza M; Seubert A; Mills KHG
    Vaccine; 2017 Sep; 35(39):5256-5263. PubMed ID: 28823618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outer membrane vesicles derived from Bordetella parapertussis as an acellular vaccine against Bordetella parapertussis and Bordetella pertussis infection.
    Bottero D; Gaillard ME; Errea A; Moreno G; Zurita E; Pianciola L; Rumbo M; Hozbor D
    Vaccine; 2013 Oct; 31(45):5262-8. PubMed ID: 24012570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of FHA and Prn on Bordetella pertussis colonization of mice is dependent on vaccine type and anatomical site.
    Zeddeman A; van Schuppen E; Kok KE; van Gent M; Heuvelman KJ; Bart MJ; van der Heide HGJ; Gillard J; Simonetti E; Eleveld MJ; van Opzeeland FJH; van Selm S; de Groot R; de Jonge MI; Mooi FR; Diavatopoulos DA
    PLoS One; 2020; 15(8):e0237394. PubMed ID: 32822419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
    Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK
    Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
    Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
    Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
    Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
    Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination.
    Smits K; Pottier G; Smet J; Dirix V; Vermeulen F; De Schutter I; Carollo M; Locht C; Ausiello CM; Mascart F
    Vaccine; 2013 Dec; 32(1):111-8. PubMed ID: 24176499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivating Immunity Primed by Acellular Pertussis Vaccines in the Absence of Circulating Antibodies: Enhanced Bacterial Control by TLR9 Rather Than TLR4 Agonist-Including Formulation.
    Auderset F; Ballester M; Mastelic-Gavillet B; Fontannaz P; Chabaud-Riou M; Reveneau N; Garinot M; Mistretta N; Liu Y; Lambert PH; Ochs M; Siegrist CA
    Front Immunol; 2019; 10():1520. PubMed ID: 31333656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of bactericidal and opsonic activity in immunity against Bordetella pertussis.
    Blanc P; Liu Y; Reveneau N; Cavell B; Gorringe A; Renauld-Mongénie G
    Expert Rev Vaccines; 2022 Dec; 21(12):1727-1738. PubMed ID: 36369768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model.
    Warfel JM; Zimmerman LI; Merkel TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):787-92. PubMed ID: 24277828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acellular pertussis vaccination facilitates Bordetella parapertussis infection in a rodent model of bordetellosis.
    Long GH; Karanikas AT; Harvill ET; Read AF; Hudson PJ
    Proc Biol Sci; 2010 Jul; 277(1690):2017-25. PubMed ID: 20200027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.
    Geurtsen J; Banus HA; Gremmer ER; Ferguson H; de la Fonteyne-Blankestijn LJ; Vermeulen JP; Dormans JA; Tommassen J; van der Ley P; Mooi FR; Vandebriel RJ
    Clin Vaccine Immunol; 2007 Jul; 14(7):821-9. PubMed ID: 17494641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenylate cyclase toxin-hemolysin relevance for pertussis vaccines.
    Sebo P; Osicka R; Masin J
    Expert Rev Vaccines; 2014 Oct; 13(10):1215-27. PubMed ID: 25090574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.